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852 The Journal of Thoracic and CardioObjective: Tumor necrosis factor  is a proinflammatory cytokine that has been
proved to play a crucial role in inducing posttransplantation lung injury. The present
study was performed to determine whether pirfenidone, a new nonpeptide drug with
potent anti–tumor necrosis factor  activity, promotes protection against acute
allograft injury through inhibiting pulmonary inflammatory responses in a rat model
of orthotopic lung transplantation.
Methods: Three transplant groups were formed: isografts, untreated allografts, and
allografts treated with pirfenidone (0.5% chow starting on day 1 after transplanta-
tion). The implants were harvested on day 21 after transplantation. Acute cellular
rejection grade and degree of allograft injury were evaluated on the basis of
hematoxylin-and-eosin staining. The pulmonary inflammatory response and inflam-
mation-induced oxidative stress were assessed on the basis of neutrophil accumu-
lation (myeloperoxidase immunoreactivity and enzymatic activity) and iron depo-
sition (Prussian blue staining). In addition, circulating levels of tissue necrosis factor
 in all animals were measured.
Results: The degree of allograft injury was significantly reduced in pirfenidone-
treated allografts relative to untreated allografts (P  .01). The beneficial effect of
pirfenidone was associated with decreased lung myeloperoxidase immunoreactivity
(P  .05) and enzymatic activity (P  .01). Moreover, the untreated allografts
contained a high concentration of iron, which was strikingly reduced by pirfenidone.
Treatment with pirfenidone resulted in a lower level of plasma tissue necrosis factor
, which correlated positively with lung myeloperoxidase enzymatic activity (P 
.0001).
Conclusion: These results suggest that pirfenidone, with its anti–tissue necrosis
factor  activity, reduced neutrophil recruitment and iron accumulation, hence
limiting the acute lung allograft injury.
Compared with other solid organs, the lung is highly immunogenic.1 Trans-plantation of this organ thus results in a relatively high incidence of acuteand chronic allograft rejection.2,3 The acute lung allograft rejection is an
inflammatory process characterized by pronounced perivascular and peribronchiolar
infiltration of inflammatory cells that could invade and destroy vessels and airways
and eventually lead to dysfunction of the lung allograft.2,3 Indeed, it was reported
that excessive inflammatory responses and overproduction of proinflammatory
cytokines exacerbate acute lung allograft injury.4-6 Pirfenidone (5-methyl-1-phenyl-
2-[1H]-pyridone) is a new nonpeptide drug with excellent oral absorption and
hepatic metabolism.7 In an open-label phase II study in patients with end-stage
idiopathic pulmonary fibrosis, treatment with pirfenidone safely restored pulmonary
function and improved survival.8 In addition to its well-documented antifibrotic
property, pirfenidone is also a potent anti-inflammatory agent. It was found that
pirfenidone could effectively inhibit bleomycin-induced acute lung inflammation9
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major proinflammatory cytokine, tumor necrosis factor 
(TNF-).10-14 It has been established that TNF- plays an
important role in the pathogenesis of acute lung allograft
rejection.4-6 Given that pirfenidone is a currently available
therapeutic agent for human use,7,8 it is thus very interesting
to determine whether this compound, with its potent anti-
TNF- property, promotes protection against acute allograft
injury by limiting the pulmonary inflammatory response.
This study evaluated whether pirfenidone reduced lung al-
lograft injury and the inflammatory response in a rat lung
transplant model.
Methods
Materials
All chemicals and reagents were purchased from Sigma Chemical
Company (St Louis, Mo) unless otherwise specified.
Animal Model
Specific pathogen-free male Lewis and Sprague-Dawley (SD) rats
(weight, approximately 300 g) were purchased from Harlan
Sprague-Dawley (Indianapolis, Ind) and housed and cared for in
the Animal Care Center at the University of Florida in accordance
with institutional guidelines. The experimental protocol was ap-
proved by the Animal Care Committee of the University of
Florida.
The orthotopic transplantation of the left lung was performed as
previously reported,15 with slight modifications. In brief, the donor
rat was anesthetized in a glass chamber constantly perfused with
5% isoflurane in oxygen for a period of 10 minutes. The animal
was then intubated orotracheally with a 14-gauge Teflon angio-
catheter and mechanically ventilated with a volume-controlled
ventilator (Harvard Rodent Ventilator, model 683; Harvard Appa-
ratus, South Natick, Mass) with 2% isoflurane in oxygen at a rate
of 80 breaths/min, a tidal volume of 10 mL/kg, and an inspired
fraction of oxygen of 1.0. The animal was heparinized (1000 U/kg
body weight administered intravenously), and a median laparoster-
notomy was performed. The main pulmonary artery was cannu-
lated through an anterior incision in the right ventricular outflow
tract, and the lungs were flushed with 20 mL of ice-cold low-
potassium-dextran preservation solution (Perfadex; Vitrolife, Go-
tenberg, Sweden) at a pressure of 20 cm H2O. The entire heart-
lung block was removed, with the lungs inflated at tidal volume.
Sixteen-gauge and 14-gauge angiocatheter cuffs were placed in the
pulmonary artery and pulmonary vein, respectively. The lung with
cuffs was stored in the low-potassium-dextran preservation solu-
tion at 4°C in a sterile beaker until implantation.
The recipient rat was intubated orotracheally and ventilated
with 2% isoflurane in oxygen at a rate of 80 breaths/min, a tidal
volume of 10 mL/kg, an inspired fraction of oxygen of 1.0, and a
positive end-expiratory pressure of 2 cm H2O. A left thoracotomy
was made through the fourth intercostal space, and the left pul-
monary artery, vein, and bronchus were isolated and clamped
proximally with microvascular clips, respectively. A small ventral
incision was made in each of the blood vessels to enable introduc-
tion of the respective donor’s blood vessels and their cuffs. The
donor and recipient bronchi were anastomosed with a running 8-0
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tilation of the graft were restored by removing clamps from the
pulmonary vein, artery, and bronchus, respectively. All transplan-
tation procedures were performed by one author (H.L.) under
sterile conditions. Isoflurane (5%) was the only anesthetic agent
given to the donor and recipient animals throughout the experi-
mental period to minimize the possible negative effects of anes-
thetics on lung graft function.
Experimental Designs
Three transplantation groups with 6 transplantations in each group
were studied: SD donor and SD recipient (isografts), Lewis to SD
rats (untreated allografts), and Lewis to pirfenidone-fed SD rats
(pirfenidone-treated allografts). Pirfenidone (Department of
Chemistry, University of Florida), 0.5% in chow, was started on
day 1 after transplantation. The pirfenidone dose was selected on
the basis of prevention of allograft injury in other animal models
in previous studies.16 In addition, 6 left lungs taken from body
weight–matched untreated male SD rats were used as a normal
control group. No immunosuppressive therapy was administered to
animals at any time during the experimental period. All animals
were killed 21 days after transplantation.
At the end of each study, animals were intubated orotracheally
and ventilated with 2% isoflurane in oxygen. One milliliter of
blood was collected from the abdominal vein in each animal. Then
the lungs were flushed through the main pulmonary artery with
ice-cold saline until they turned white. A straight, fine hemostatic
forceps was applied across the transplanted (left) lung just below
the hilum so that the lung was divided into 2 parts. The lower part
was snap-frozen in liquid nitrogen for biochemical studies, and the
remaining lung was inflated with 2 mL of 10% neutral-buffered
formalin, fixed overnight, and embedded in paraffin wax.
Morphologic Evaluation
The paraffin-embedded lung block was cut into 4-m sections and
stained with hematoxylin and eosin. The severity of acute cellular
rejection (ACR) was graded as A0 to 4 on the basis of the revised
“Working Formation for the Classification of Pulmonary Allograft
Rejection” according to the presence and extent of perivascular
and interstitial mononuclear cell infiltrates,17 as described previ-
ously.15 Preservation of alveolar architecture was determined by
converting the light microscopy fields into digital format with an
Optronics digital camera with Magna Fire software (Optronics,
Goleta, Calif) to assess the degree of lung graft injury in general.
The images were analyzed with Spot Advanced software (Diag-
nostic Instruments, Sterling Heights, Mich). The damaged alveolar
architecture includes edema, congestion, hemorrhage, hyaline
membranes, and necrosis. The degree of lung injury was expressed
as the percentage of area with damaged alveolar architecture to
total lung area. The morphologic study was performed by a lung
pathologist (P.D.) in a blinded fashion.
Myeloperoxidase Expression and Enzymatic Activity
Separate paraffin-embedded sections were immunohistochemi-
cally stained with myeloperoxidase (MPO) by the avidin-biotin-
peroxidase complex method.18 In brief, after antigen retrieval with
Trilogy solution (Cell Marque Corp, Hot Springs, Ark), the lung
sections were incubated overnight at 4°C with primary polyclonal
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tions. After being washed 3 times with phosphate-buffered saline,
the sections were further incubated for 1 hour at room temperature
with biotinylated goat anti-rabbit secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, Calif) at a dilution of 1:400. The
specific MPO binding was detected with streptavidin-biotinylated
horseradish peroxidase complex (Vectstain ABC kit; Vector Lab-
oratories Inc, Burlingame, Calif) and visualized with diaminoben-
zidine. Nuclei were counterstained with hematoxylin. Negative
control sections were included in each staining run, with the
primary antibody being replaced by normal rabbit immunoglobulin
G (Santa Cruz Biotechnology). None of the negative control sec-
tions showed positive staining. The number of MPO-positive cells
was counted in 10 randomly chosen microscopic high-power fields
(400) per graft in a blinded fashion.15
Quantitative MPO enzymatic activity in lung tissue was deter-
mined with a commercial MPO assay kit (CytoStore, Alberta,
Canada). In brief, frozen lung tissue was homogenized on ice in 50
mmol/L Tris-HCl buffer (pH 7.4) containing 2% protease inhibitor
cocktail and 5 mg/mL hexadecyltrimethylammonium bromide.
The homogenized samples were centrifuged for 15 minutes at
3000g (4°C), and 20 L of the supernatants was collected and
mixed with 200 L of 20 mmol/L potassium phosphate buffer (pH
7.0) containing 0.167 mg/mL o-dianisidine dihydrochloride and
0.0005% hydrogen peroxide. Change in absorbance over 1 minute
was measured spectrophotometrically at 450 nm. Protein concen-
tration for all samples was determined by using a BCA protein
assay kit (Pierce, Rockford, IL), with bovine serum albumin as the
standard. The final results of MPO activity were expressed as the
change in absorbance per minute per milligram of protein.
Assessment of Iron Deposition
Prussian blue staining is widely used for assessment of iron dep-
osition in tissues.19,20 In brief, after deparaffinization and rehydra-
tion, the lung sections were treated with 20% hydrochloric acid
solution to liberate ferric iron and further treated with 10% aque-
ous potassium ferrocyanide solution to produce insoluble ferric
ferrocyanide. The sections were then counterstained with eosin.
This staining identifies ferric iron as bright blue and nuclei as red.
The standard procedure for this staining was provided by the
clinical histology laboratory at the Veterans Affairs Hospital,
University of Florida.
Determination of Plasma TNF- Level
The plasma concentration of TNF- was determined by a com-
mercial rat TNF- ELISA kit (R&D systems, Minneapolis, Minn),
according to the manufacturer’s instruction. The rat TNF- assay
has no cross-reactivity with other cytokines, such as interleukin 1
(IL-1), IL-2, or IL-4. The final results were expressed as picograms
per milliliter.
Statistical Analysis
Data are expressed as means  standard error of the mean (SEM),
and statistical analyses were performed with the Prism statistical
program (GraphPad, San Diego, Calif). A nonparametric analysis
of variance, the Kruskal-Wallis test with the Dunn multiple com-
parisons test, was used to determine the difference between ACR
grades. One-way analysis of variance with the Newman-Keuls test
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MPO-positive cells, MPO enzymatic activity, and plasma TNF-
levels between the different groups. Linear correlation was eval-
uated with the Pearson r coefficient.
Results
Representative microphotographs of hematoxylin and eosin–
stained lung tissue from each of the 4 groups are shown in
Figure 1, A through D. An occasional lung isograft showed
very mild lymphocytic infiltrates in perivascular locations,
whereas the majority of lung isografts (Figure 1, B) dis-
played no detectable pathologic lesions and were similar to
normal left lungs (Figure 1, A), indicating that surgical
trauma and the ischemia-reperfusion process had very little
effect on graft morphologic property. In contrast, untreated
lung allografts displayed end-stage ACR, with dense infil-
tration of mononuclear cells around the vessels and airways
and in the interstitium. In addition, there is evidence of
necrosis with interstitial edema, thickening of the wall of
small airways and vessels, and destruction of alveolar-
interstitial structure (Figure 1, C). Notably, a markedly
reduced interstitial infiltration of mononuclear cells with a
widespread preservation of alveolar architecture was found
in pirfenidone-treated allografts (Figure 1, D). ACR grade
was significantly greater in untreated allografts compared
with that in the normal lung or isograft groups (P  .05).
Pirfenidone might have reduced ACR grade, but the ACR in
the pirfenidone-treated allograft group was not significantly
different (P  .056) from that in the untreated allograft
group (Figure 1, E). Importantly, much less lung injury, as
determined on the basis of preservation of alveolar archi-
tecture, was found in the pirfenidone-treated allografts
(24.2%  12.6% of damaged area/total area) in comparison
with the untreated allografts (67.4%  14.3%, P  .01;
Figure 1, F).
The histologic study revealed that pirfenidone is protec-
tive against acute allograft injury. We next explored
whether the beneficial effect of pirfenidone was linked to
inhibited pulmonary inflammatory responses. For this, we
first measured the effect of pirfenidone on lung MPO im-
munoreactivity and enzymatic activity, which reflects neu-
trophil recruitment.18,21,22 Representative microphoto-
graphs of MPO-immunostained lung sections of a normal
left lung and an untreated lung allograft are shown in Figure
2, A. Scarce MPO staining was apparent in the normal left
lungs and isografts. By contrast, a large number of MPO-
positive cells were seen in untreated allografts (40.8  8.4
MPO-stained cells/400 field), which was significantly re-
duced (P  .05) by pirfenidone (24.8  3.9 MPO-stained
cells/400 field; Figure 2, B). MPO immunochemical stain-
ing was mirrored by MPO enzymatic activity, which
showed that untreated allografts contained a higher level of
MPO activity (2.0  0.16  absorbance per minute per
milligram of protein) in comparison with pirfenidone-
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milligram of protein, P  .01 vs untreated allografts; Figure
2, C). With the knowledge that the pulmonary inflammatory
Figure 2. Lung MPO expression and enzymatic activity. MPO immu-
nohistochemically stained sections of a normal left lung and an
untreated lung allograft. MPO-positive cells are brown in color (A).
The number of MPO-positive cells per high-power field (400) and
lung MPO enzymatic activity in all groups are shown in B and C,
respectively. Results are presented as means SEM (n 6 in each
group). *P <.05 and **P < .01 versus normal left lungs or isografts;
†P < .05 and ††P < .01 versus untreated allografts.Figure 1. Histologic evaluation of lung grafts. Examples of hema-
toxylin and eosin–stained sections taken from normal left lung
(A), lung isograft (B), untreated (C), and pirfenidone (PFD)–treated
lung allograft (D). Photomicrographs are representative of 6 rats
in each group. (Original magnification 100.) E shows the grade
of ACR in all groups. In F, quantification of lung injury on the basis
of the amount of preserved alveolar architecture is shown. Re-
sults are presented as means  SEM (n  6 each group). *P <
.05 and **P < .01 versus normal left lungs or isografts; ††P < .01process is associated with excessive oxidative stress, we
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position in lung tissue.23 Indeed, we found that lung sections
from normal animals (Figure 3, A) or isografts (Figure 3, B)
stained with Prussian blue displayed no detectable iron. By
contrast, intense blue positive staining was consistently
observed in sections from untreated allografts (Figure 3, C),
whereas the amount of stainable iron was strikingly reduced
in pirfenidone-treated allografts (Figure 3, D).
Finally, we verified the anti-TNF- activity of pirfeni-
done and explored the relationship between circulating
TNF- levels and lung MPO activity. We found that plasma
TNF- concentration was similar between normal animals
(25.6  5.3 pg/mL) and animals that received isografts
(36.2  7.4 pg/mL). In contrast, a marked increase in
plasma TNF- levels was found in animals receiving allo-
grafts (271.4  27.6 pg/mL, P  .01 vs normal animals or
animals receiving isografts). The higher plasma TNF-
concentration was significantly reduced by pirfenidone
treatment (138.9  15.1 pg/mL, P  .01 vs untreated
animals receiving allografts; Figure 4, A). In addition, we
found that the plasma TNF- level significantly (P  .0001)
positively correlated with the lung MPO activity (Figure 4, B).
Discussion
Pirfenidone has been proved to be effective for patients with
idiopathic pulmonary fibrosis8 and multiple sclerosis.7 The
potential therapeutic adaptation of pirfenidone could be
further expanded by the present discovery, in which we
found that continuous monotherapy with pirfenidone dra-
Figure 3. Iron loading in lung tissue. Sample of Prussian blue–
stained sections taken from normal left lung (A), lung isograft (B),
untreated (C), and pirfenidone-treated lung allograft (D). Photomi-
crographs are representative of 6 rats in each group. (Original
magnification 200.) Note that the intensive blue positive stain-
ing observed in the untreated lung allograft was strikingly re-
duced in pirfenidone-treated lung allografts.matically reduced the severity of allograft injury in a rat
856 The Journal of Thoracic and Cardiovascular Surgery ● Septlung transplant model (Figure 1). Given that pirfenidone
was tolerated with relatively minor adverse effects and no
toxic effect was found in patients,7,8 the present observation
suggests that pirfenidone is a candidate drug to be evaluated
for attenuation of posttransplantation lung injury in human
subjects.
In the present study a rat lung transplant model with the
combination of Lewis donors and SD recipients was used.
In this model increased longevity of posttransplantation
survival was associated with more severe ACR, whereas
ischemia-reperfusion caused very little lung damage.15 Ac-
cordingly, we assessed the lung allografts at a relatively late
time point, 21 days after transplantation. Indeed, we found
that the untreated lung allografts displayed end-stage ACR
with widespread destruction of alveolar-interstitial structure
(Figure 1). Moreover, the severe pathologic lesion was
Figure 4. Circulating TNF- level. A, Plasma TNF- levels in all
groups. Results are presented as means  SEM (n  6 in each
group). **P < .01 versus normal animals or animals receiving
isografts; ††P< .01 versus untreated animals receiving allografts.
B, Plasma TNF- levels positively correlated with lung MPO
activity (r2  0.88, P < .001).accompanied by massive infiltration of neutrophils, as evi-
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and MPO enzymatic activity (Figure 2). These findings
concur with previous results demonstrating that increased
neutrophil recruitment occurred in human lung allografts
with higher ACR grades.20,24 Neutrophils contain MPO, and
this enzyme catalyzes the reaction between hydrogen per-
oxide and chloride to form a highly reactive species, hypo-
chlorous acid.25 Thus the infiltration of neutrophils in lung
allografts would lead to an increase in oxidative stress. The
excess oxidative stress was further confirmed by the finding
of iron accumulation in untreated lung allografts (Figure
3).23 It is established that excessive oxidative stress causes
tissue damage by means of protein inactivation, lipid per-
oxidation, and DNA damage.24,26,27 Indeed, a clinical study
revealed that the neutrophil population in bronchoalveolar
lavage fluid positively correlated with mortality in human
lung recipients.28 Thus, our finding that pirfenidone dramat-
ically decreased neutrophil recruitment (Figure 2) and iron
accumulation (Figure 3) suggests a mechanism by which
pirfenidone conferred protection against acute lung allograft
injury (Figure 1). Similarly, a recent study showed that
pirfenidone prevented endotoxin-induced liver injury
through decreased neutrophil infiltration.29
There is convincing evidence that pirfenidone is a potent
TNF- antagonist. For example, numerous studies have
demonstrated that pirfenidone decreased the synthesis and
release of TNF- in vivo10,12-14 and in vitro.12,14 Moreover,
it is believed that the drug inhibits the reduction of TNF-
selectively at the translational level.11 The anti-TNF- ac-
tivity of pirfenidone has also been identified in the present
study, in which we found that pirfenidone significantly
reduced circulating TNF- levels seen in animals receiving
lung allografts (Figure 4). Recent studies have revealed that
TNF- potentiates the recruitment and activation of neutro-
phils, and inhibition of TNF- results in a marked reduction
of neutrophil infiltration in lung tissue.4,21,22 Consistent
with these, we found that the circulating TNF- level was
positively correlated with lung MPO activity (Figure 4). It
thus appears that the anti-TNF- property of pirfenidone
contributed, at least in part, to the reduced neutrophil re-
cruitment seen in the pirfenidone-treated lung allografts.
However, it is presently unclear whether the decreased iron
accumulation seen in pirfenidone-treated allografts resulted
secondarily from the reduced neutrophil recruitment or a
direct drug effect. Obviously, additional studies are required
to clarify this issue.
Here we report that pirfenidone, with its anti-TNF-
activity, is effective in ameliorating acute lung allograft
injury. The compound might mediate the efficacy by inhib-
iting tissue neutrophil recruitment and iron deposition.
These findings lend further support to the notion4-6 that
TNF- plays a pivotal role in inducing acute posttransplan-
tation lung injury. Notably, an increased TNF- production
The Journal of Thoracihas been reported to be associated with more severe ACR in
human heart transplantations.30 Therefore, it would be in-
teresting to test whether treatment with pirfenidone, alone or
in combination with classic immunosuppressants, could
provide greater benefits to transplantation of thoracic organs
(eg, heart-lung) in human subjects.
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